Rat Orosomucoid 1,ORM1 ELISA Kit
- Known as:
- Rat Orosomucoid 1,ORM1 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- YHB0000Ra
- Product Quantity:
- 48T
- Category:
- Elisa Kits
- Supplier:
- yehua
- Gene target:
- Rat Orosomucoid 1 ORM1 ELISA Kit
Related genes to: Rat Orosomucoid 1,ORM1 ELISA Kit
- Gene:
- ORM1 NIH gene
- Name:
- orosomucoid 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 9q32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2014-11-19
Related products to: Rat Orosomucoid 1,ORM1 ELISA Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Sizeα - Calcitonin Gene Related Peptide, α - CGRP, rat'F 4_80 Antigen (mouse) Host Rat'F 4_80 Antigen (mouse) Host Rat(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit Related articles to: Rat Orosomucoid 1,ORM1 ELISA Kit
- Sterols and sphingolipids assemble into specialized membrane microdomains that are essential for membrane function, protein sorting, and signal transduction. Although coordinated regulation between sterol and sphingolipid metabolic pathways has long been recognized, the molecular mechanisms mediating this cross-talk remain incompletely defined. Here, we uncover an unanticipated role for the conserved yeast Orm proteins in controlling sterol and neutral lipid homeostasis. Deletion of and causes hypersensitivity to sterol biosynthesis inhibitors, accumulation of steryl esters, and an increase in lipid droplet number. Consistent with mutants lacking core neutral lipid hydrolases, cells display a marked defect in neutral lipid mobilization. These phenotypes depend on sphingolipid pathway perturbation but cannot be attributed to sphingolipid accumulation alone. Together, these findings position the Orm proteins as regulatory nodes linking sterol metabolism, lipid droplet dynamics, and sphingolipid biosynthesis. - Source: PubMed
Publication date: 2026/04/30
Barone FrancescaCottier StéphanieStribny JiriVisentin MicheleSchneiter RogerLone Museer A - Psoriasis is a complex chronic inflammatory skin disease. While typical cases are often diagnosed based on clinical features, achieving objective assessment of disease activity and precise early-stage identification remains a clinical focus. This study aims to evaluate the diagnostic value of monocytes (MONO), Orosomucoid-1 (ORM1), Orosomucoid-2 (ORM2), and Alpha-1-acid glycoprotein (AGP), and to develop a nomogram for the objective and early identification of psoriasis. - Source: PubMed
Publication date: 2026/04/21
Liu JuanliHu QingqingZhang QianjinZheng Renshan - Previous studies have shown that non coding RNA (ncRNA) is closely related to the occurrence and development of acute ischemic stroke (AIS), but its systemic regulatory disease profile has not been fully elucidated. We collected peripheral whole blood samples from AIS patients and healthy controls for transcriptome expression profiling analysis of mRNA, micro RNA, and long non coding RNA (lncRNA). In transcriptome data analysis, differentially expressed RNAs were identified, and key functional pathways and microenvironmental changes in AIS were comprehensively analyzed. Based on the ceRNA hypothesis, a competitive regulatory network of ceRNA (lncRNA/miRNA/mRNA) for AIS disease occurrence was constructed. In downstream analysis, the upregulated mRNA in the ceRNA network was combined with drug target molecular information in the Drugbank database to screen and identify three direct targets, NFKBIA, TNFAIP6, and ORM1, all of which play key immunomodulatory and anti-inflammatory roles in the pathological process of AIS; Further combining with the PPI network, FN1 and MMP9 were identified as key predictive targets. Constructing a multi-level and multi-omics network map of drug protein ceRNA to explore the transformation pathway from molecular mechanisms to clinical drug targets. Molecular docking simulation was used to verify that the predicted targets FN1 and MMP9 can bind to current therapeutic drugs such as Acetylsalicylic acid, suggesting the possibility of FN1 and MMP9 as new targets for AIS treatment. This study follows a systematic strategy from constructing transcriptome regulatory networks to downstream clinical drug target validation, providing a new perspective for the occurrence and development of AIS diseases from the RNA regulatory level. The multi-omics landscape reveals potential molecular mechanisms and lays a solid theoretical foundation for identifying novel and reliable diagnostic biomarkers and potential therapeutic targets. - Source: PubMed
Publication date: 2026/04/09
Kong XiaoliChen ZhengyuLu HanGao XuetingZhou XiaoyuSu HaoTeng JunYou HaimengGe Hongyan - The search for new biomarkers that allow an early diagnosis in sepsis has become a necessity in medicine. This study aims to identify protein biomarkers that differentiate sepsis from non-infectious systemic inflammatory response syndrome (NISIRS), addressing the need for early sepsis diagnosis. - Source: PubMed
Publication date: 2026/04/24
Ruiz-Sanmartín AdolfoRibas VicentSuñol DavidChiscano-Camón LuisMartín LauraBajaña IvánBastida JulianaLarrosa NievesGonzález Juan JoséCarrasco María DoloresCanela NúriaFerrer RicardRuiz-Rodríguez Juan Carlos - Pancreatic cancer ranks as the third leading cause of cancer-related deaths in the United States, with a dismal 5-year survival rate of only 13%. This poor prognosis is largely due to the challenge of early detection, which is crucial for effective treatment. Given the low prevalence of pancreatic ductal adenocarcinoma (PDAC), widespread screening is impractical and economically unfeasible. We present a novel, multiplex blood-based assay aimed to improve early detection for PDAC in high-risk populations. - Source: PubMed
Publication date: 2026/04/21
Pan ShengKarki RameshLai Lisa ACreighton Chad JBrentnall Teresa ABrand Randall EChen Ru